Emilia I. Sato

Otonis Street, 863, 2 Floor, Vila Clementino
Sao Paulo, SP 04025002, Brazil

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 72 publications

Protective effect of antimalarials on the most frequently affected damage domains in SLE: Data from a multiethnic Latin American cohort.

Protective effect of antimalarials on the most frequently affected damage domains in SLE: Data from a multiethnic Latin American cohort.

Journal: Lupus

Published: February 25, 2026

Impact of SARS-CoV-2 Vaccination on Disease Activity and Severity of COVID-19 Infection in Patients with Systemic Lupus Erythematosus: A Multicenter Cohort Study.

Impact of SARS-CoV-2 Vaccination on Disease Activity and Severity of COVID-19 Infection in Patients with Systemic Lupus Erythematosus: A Multicenter Cohort Study.

Journal: Vaccines

Published: September 07, 2025

Primary and Booster COVID-19 Vaccination in Patients with Sjögren's Disease: Data from the Longitudinal SAFER Cohort Study.

Primary and Booster COVID-19 Vaccination in Patients with Sjögren's Disease: Data from the Longitudinal SAFER Cohort Study.

Journal: Vaccines

Published: July 30, 2025

Immunogenicity and safety to SARS-Cov-2 vaccination in patients with systemic vasculitis.

Immunogenicity and safety to SARS-Cov-2 vaccination in patients with systemic vasculitis.

Journal: Frontiers in immunology

Published: June 28, 2025

Evaluation of clinical, histological and biomarker response after initial therapy of lupus nephritis.

Evaluation of clinical, histological and biomarker response after initial therapy of lupus nephritis.

Journal: Lupus science & medicine

Published: June 23, 2025

Immunogenicity and safety of BNT162b2 vaccine in patients with juvenile immune mediated inflammatory disease.

Immunogenicity and safety of BNT162b2 vaccine in patients with juvenile immune mediated inflammatory disease.

Journal: Pediatric research

Published: June 19, 2025

Item-specific factors associated with damage accrual in systemic lupus erythematosus: insights from a multiethnic, multinational Latin American cohort.

Item-specific factors associated with damage accrual in systemic lupus erythematosus: insights from a multiethnic, multinational Latin American cohort.

Journal: Lupus science & medicine

Published: March 11, 2025

Validation cohort of a tool to predict proliferative histological class in lupus nephritis based on clinical and laboratory data: LUCAS Study (Lupus Nephritis Class Assessment System).

Validation cohort of a tool to predict proliferative histological class in lupus nephritis based on clinical and laboratory data: LUCAS Study (Lupus Nephritis Class Assessment System).

Journal: Lupus science & medicine

Published: February 10, 2025

Comparison of the immunogenicity and safety among COVID-19 vaccines ChadOx-1, CoronaVac and BNT162b2 in systemic lupus erythematosus (SLE) patients: a prospective cohort.

Comparison of the immunogenicity and safety among COVID-19 vaccines ChadOx-1, CoronaVac and BNT162b2 in systemic lupus erythematosus (SLE) patients: a prospective cohort.

Journal: Advances in rheumatology (London, England)

Published: December 26, 2024

Immunogenicity of SARS-CoV-2 Vaccination Schedules Including a Booster Dose in Patients with Systemic Lupus Erythematosus: Data from a Prospective Multicenter Study.

Immunogenicity of SARS-CoV-2 Vaccination Schedules Including a Booster Dose in Patients with Systemic Lupus Erythematosus: Data from a Prospective Multicenter Study.

Journal: Vaccines

Published: November 15, 2024

Correction to: II Brazilian Society of Rheumatology consensus for lupus nephritis diagnosis and treatment.

Correction to: II Brazilian Society of Rheumatology consensus for lupus nephritis diagnosis and treatment.

Journal: Advances in rheumatology (London, England)

Published: October 30, 2024

Immunogenicity and Safety According to Immunosuppressive Drugs and Different COVID-19 Vaccine Platforms in Immune-Mediated Disease: Data from SAFER Cohort.

Immunogenicity and Safety According to Immunosuppressive Drugs and Different COVID-19 Vaccine Platforms in Immune-Mediated Disease: Data from SAFER Cohort.

Journal: Vaccines

Published: October 29, 2024

Showing 1-12 of 72

Last Updated: 09/26/2026